6,550 research outputs found
Transcriptomic analysis of canine B and T cell lymphoma
Gene expression profiling in human lymphoma has identified a number of genes and pathways of prognostic value that could also be used as targets for therapy.
The aim of the present study was to compare gene expression in canine B-cell lymphoma, T-cell lymphoma and control lymph node samples using RNA-Seq to identify differentially expressed pathways which may have a role in pathogenesis and could be used as possible treatment targets.
RNA was extracted from lymph node tissue collected from six dogs with B-cell lymphoma, five dogs with T-cell lymphoma, one dog with B and T-cell lymphoma and eight controls. The RNA was sequenced using an Illumina NextSeq500 platform, reads were aligned to the current canine genome and gene expression profiles were determined for each group. Pathway analysis was also performed to identify networks enriched for differentially expressed genes together with activated and repressed molecular pathways. After stand-alone analysis of the dataset, it was combined with a previous dataset representing eighteen dogs with B-cell lymphoma and five dogs with T-cell lymphoma in order to increase the power of the analysis.
Principal component analysis revealed that the three groups, i.e. B-cell lymphoma, T-cell lymphoma and controls, formed separate clusters with distinct expression signatures. Network analysis highlighted different pathways overrepresented in each type of lymphoma. In B-cell lymphoma tissue, the NF-ĸB pathway, cell cycle control and DNA repair pathways were over-represented with overexpression of ribosomal and minichromosome maintenance proteins also noted. In contrast for T-cell lymphomas, mRNA synthesis, FGFR and RUNX pathways were highlighted together with those relating to innate immunity.
This project identified several aberrant pathways in B-cell and T-cell lymphoma that have not previously been reported and which can be considered candidate targets for developing novel treatment, thereby informing future studies
Recent advances in the extraction, purification, structural-property correlations, and antiobesity mechanism of traditional Chinese medicine-derived polysaccharides: a review
Traditional Chinese medicine (TCM) has displayed preventive and therapeutic effects on many complex diseases. As natural biological macromolecules, TCM-derived antiobesogenic polysaccharides (TCMPOs) exhibit notable weight-loss effects and are seen to be a viable tactic in the fight against obesity. Current studies demonstrate that the antiobesity activity of TCMPOs is closely related to their structural characteristics, which could be affected by the extraction and purification methods. Therefore, the extraction, purification and structural-property correlations of TCMPOs were discussed. Investigation of the antiobesity mechanism of TCMPOs is also essential for their improved application. Herein, the possible antiobesity mechanisms of TCMPOs are systematically summarized: (1) modulation of appetite and satiety effects, (2) suppression of fat absorption and synthesis, (3) alteration of the gut microbiota and their metabolites, and (4) protection of intestinal barriers. This collated information could provide some insights and offer a new therapeutic approach for the management and prevention of obesity
The application and sustainable development of coral in traditional medicine and its chemical composition, pharmacology, toxicology, and clinical research
This review discusses the variety, chemical composition, pharmacological effects, toxicology, and clinical research of corals used in traditional medicine in the past two decades. At present, several types of medicinal coral resources are identified, which are used in 56 formulas such as traditional Chinese medicine, Tibetan medicine, Mongolian medicine, and Uyghur medicine. A total of 34 families and 99 genera of corals are involved in medical research, with the Alcyoniidae family and Sarcophyton genus being the main research objects. Based on the structural types of compounds and the families and genera of corals, this review summarizes the compounds primarily reported during the period, including terpenoids, steroids, nitrogen-containing compounds, and other terpenoids dominated by sesquiterpene and diterpenes. The biological activities of coral include cytotoxicity (antitumor and anticancer), anti-inflammatory, analgesic, antibacterial, antiviral, immunosuppressive, antioxidant, and neurological properties, and a detailed summary of the mechanisms underlying these activities or related targets is provided. Coral toxicity mostly occurs in the marine ornamental soft coral Zoanthidae family, with palytoxin as the main toxic compound. In addition, nonpeptide neurotoxins are extracted from aquatic corals. The compatibility of coral-related preparations did not show significant acute toxicity, but if used for a long time, it will still cause toxicity to the liver, kidneys, lungs, and other internal organs in a dose-dependent manner. In clinical applications, individual application of coral is often used as a substitute for orthopedic materials to treat diseases such as bone defects and bone hyperplasia. Second, coral is primarily available in the form of compound preparations, such as Ershiwuwei Shanhu pills and Shanhu Qishiwei pills, which are widely used in the treatment of neurological diseases such as migraine, primary headache, epilepsy, cerebral infarction, hypertension, and other cardiovascular and cerebrovascular diseases. It is undeniable that the effectiveness of coral research has exacerbated the endangered status of corals. Therefore, there should be no distinction between the advantages and disadvantages of listed endangered species, and it is imperative to completely prohibit their use and provide equal protection to help them recover to their normal numbers. This article can provide some reference for research on coral chemical composition, biological activity, chemical ecology, and the discovery of marine drug lead compounds. At the same time, it calls for people to protect endangered corals from the perspectives of prohibition, substitution, and synthesis
Therapeutic targets and potential delivery systems of melatonin in osteoarthritis
Osteoarthritis (OA) is a highly prevalent age-related musculoskeletal disorder that typically results in chronic pain and disability. OA is a multifactorial disease, with increased oxidative stress, dysregulated inflammatory response, and impaired matrix metabolism contributing to its onset and progression. The neurohormone melatonin, primarily synthesized by the pineal gland, has emerged as a promising therapeutic agent for OA due to its potential to alleviate inflammation, oxidative stress, and chondrocyte death with minimal adverse effects. The present review provides a comprehensive summary of the current understanding regarding melatonin as a promising pharmaceutical agent for the treatment of OA, along with an exploration of various delivery systems that can be utilized for melatonin administration. These findings may provide novel therapeutic strategies and targets for inhibiting the advancement of OA
Adaptations in physiological and neuronal function during diet-induced obesity
Obesity significantly increases the risk of developing chronic conditions including type II diabetes, cardiovascular disease, and some cancers. The rate of obesity has tripled globally since 1975, which is in part due to the sudden prevalence and overconsumption of palatable high-fat diets (HFDs). Obesity profoundly perturbs the neural control of energy balance, affecting diverse cell types within the hypothalamus. However, an incomplete understanding of how HFD impacts the regulation of energy balance hinders our ability to more effectively treat obesity.
In this thesis, I describe the physiological and neuronal response to HFD feeding in rodents. We identified that HFD exposure elevates the body weight set point, which is initially driven by a transient hyperphagia. This hyperphagia coincides with increased excitatory transmission to lateral hypothalamic orexin (ORX) neurons, which regulate acute food intake. This suggests that ORX neurons may be involved in the initial hyperphagia, implicating them in the development of obesity. As HFD prolongs, body weight gain slows and reaches a new steady state regardless of age at the start, duration of feeding, or palatability of the diet. This sustained weight coincides with increased synaptic contacts to melanin-concentrating hormone (MCH) neurons, which promote weight gain and food intake, likely contributing to the maintenance of obesity.
The molecular mechanism underlying the establishment of a new set point remains elusive. During HFD feeding, the presence of a chronic low-grade
hypothalamic inflammation exacerbates weight gain, therefore we reasoned that inflammatory factors could modulate appetite-promoting neurons to maintain a new set point. We found that the inflammatory mediator prostaglandin E2 (PGE2) activate MCH neurons via its EP2 receptor (EP2R). Suppressing PGE2-EP2R on MCH neurons partially protects against excess weight gain and fat accumulation in the liver during HFD feeding. This mechanism could contribute to the maintenance of an elevated body weight set point in during diet-induced obesity.
Without long-term treatment options in face of the increasing rates of obesity, we are in desperate need of novel interventions. In the future, we hope that targeting EP2R on MCH neurons can lower body weight set point and aid in combatting obesity
Viral infections and complications in inflammatory bowel disease
This thesis aimed to clarify the impact of several viral infections, their complications and vaccination responses in patients with inflammatory bowel disease (IBD). The first part focuses on two herpes viruses, Epstein-Barr virus (EBV) and cytomegalovirus (CMV), that can cause severe opportunistic infections, mostly as a rare complication of the use of immunosuppressants. In the second part we studied the risk of the premalignant condition cervical intraepithelial neoplasia (CIN) and cervical cancer caused by human papillomavirus (HPV) in women with IBD and we aimed to identify risk factors, in particular by studying the exposure to immunosuppressants in detail. The third part describes an uncommon case of a hepatitis E virus (HEV) infection in a patient using the gut-selective biologic agent vedolizumab. In the last part of this thesis, we focused on vaccination responses to influenza vaccination and severe acute respiratory coronavirus 2 (SARS-Cov-2) vaccination in immunocompromised patients with IBD and other immune-mediated inflammatory diseases (IMID)
Identifying alterations in adipose tissue-derived islet GPCR peptide ligand mRNAs in obesity: implications for islet function
In addition to acting as an energy reservoir, white adipose tissue is a vital endocrine organ involved in the modulation of cellular function and the maintenance of metabolic homeostasis through the synthesis and secretion of peptides, known as adipokines. It is known that some of these secretory peptides play important regulatory roles in glycaemic control by acting directly on islet β-cells or on insulin-sensitive tissues. Excess adiposity causes alterations in the circulating levels of some adipokines which, depending on their mode of action, can have pro-inflammatory, pro-diabetic or anti-inflammatory, anti-diabetic properties. Some adipokines that are known to act at β-cells have actions that are transduced by binding to G protein- coupled receptors (GPCRs). This large family of receptors represents ~35% of all current drug targets for the treatment of a wide range of diseases, including type 2 diabetes (T2D). Islets express ~300 GPCRs, yet only one islet GPCR is currently directly targeted for T2D treatment. This deficit represents a therapeutic gap that could be filled by the identification of adipose tissue-derived islet GPCR peptide ligands that increase insulin secretion and overall β-cell function. Thus, by defining their mechanisms of action, there is potential for the development of new pharmacotherapies for T2D. Therefore, this thesis describes experiments which aimed to compare the expression profiles of adipose tissue-derived islet GPCR peptide ligand mRNAs under lean and obese conditions, and to characterise the functional effects of a selected candidate of interest on islet cells. Visceral fat depots were retrieved from high-fat diet-induced and genetically obese mouse models, and from human participants. Fat pads were either processed as whole tissue, or mature adipocyte cells were separated from the stromal vascular fraction (SVF) which contains several other cell populations, including preadipocytes and macrophages. The expression levels of 155 islet GPCR peptide ligand mRNAs in whole adipose tissue or in isolated mature adipocytes were quantified using optimised RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) protocols. Comparisons between lean and obese states in mice models and humans revealed significant modifications in the expression levels of several adipokine mRNAs. As expected, mRNAs encoding the positive control genes, Lep and AdipoQ were quantifiable, with the expression of Lep mRNA increasing and that of AdipoQ mRNA decreasing in obesity. Expression of Ccl4 mRNA, encoding chemokine (C-C motif) ligand 4, was significantly upregulated in whole adipose tissue across all models of obesity compared to their lean counterparts. This coincided with elevated circulating Ccl4 peptide levels. This increase was not replicated in isolated mature adipocytes, indicating that the source of upregulated Ccl4 expression in obesity was the SVF of adipose tissue. Based on this significant increase in Ccl4 mRNA expression within visceral fat and its undetermined effects on β-cell function, Ccl4 was selected for further investigation in MIN6 β-cells and mouse islets. PRESTO-Tango β-arrestin reporter assays were performed to determine which GPCRs were activated by exogenous Ccl4. Experiments using HTLA cells expressing a protease-tagged β- arrestin and transfected with GPCR plasmids of interest indicated that 100ng/mL Ccl4 significantly activated Cxcr1 and Cxcr5, but it was not an agonist at the previously identified Ccl4-target GPCRs Ccr1, Ccr2, Ccr5, Ccr9 and Ackr2. RNA extraction and RT-qPCR experiments using MIN6 β-cells and primary islets from lean mice revealed the expression of Cxcr5 mRNA in mouse islets, but it was absent in MIN6 β-cells. The remaining putative Ccl4 receptors (Ccr1, Ccr2, Ccr5, Ccr9, Cxcr1 and Ackr2) were either absent or present at trace levels in mouse islets and MIN6 β-cells. Recombinant mouse Ccl4 protein was used for functional experiments at concentrations of 5, 10, 50 and 100ng/mL, based on previous reports of biological activities at these concentrations. Trypan blue exclusion testing was initially performed to assess the effect of exogenous Ccl4 on MIN6 β-cell viability and these experiments indicated that all concentrations (5-100ng/mL) were well-tolerated. Since β-cells have a low basal rate of apoptosis, cell death was induced by exposure to the saturated free fatty acid, palmitate, or by a cocktail of pro-inflammatory cytokines (interleukin-1β, tumour necrosis factor-α and interferon-γ). In MIN6 β-cells, Ccl4 demonstrated concentration-dependent protective effects against palmitate-induced and cytokine-induced apoptosis. Conversely, while palmitate and cytokines also increased apoptosis of mouse islets, Ccl4 did not protect islets from either inducer. Quantification of bromodeoxyuridine (BrdU) incorporation into β-cell DNA indicated that Ccl4 caused a concentration-dependent reduction in proliferation of MIN6 β-cells in response to 10% fetal bovine serum (FBS). In contrast, immunohistochemical quantification of Ki67-positive mouse islet β-cells showed no differences in β-cell proliferation between control- and Ccl4-treated islets. Whilst the number of β-cells and δ-cells were unaffected, α- cells were significantly depleted by Ccl4 treatment. Exogenous Ccl4 had no effect on nutrient- stimulated insulin secretion from both MIN6 β-cells and primary mouse islets. The 3T3-L1 preadipocyte cell line was used to assess potential Ccl4-mediated paracrine and/or autocrine signalling within adipose tissue. Ccl4 did not alter the mRNA expression of Pparγ, a master regulator of adipocyte differentiation, but did significantly downregulate the mRNA expression of the crucial adipogenic gene, adiponectin. Oil Red O staining and Western blotting were performed to assess lipid accumulation, and insulin and lipolytic signalling, respectively, and these experiments indicated that the observed Ccl4-induced decrease in adiponectin expression failed to correlate with any changes in adipocyte function. In summary, these data demonstrated anti-apoptotic and anti-proliferative actions of the adipokine, Ccl4, on MIN6 β-cells that were not replicated in mouse islets. The absence of any anti-apoptotic, insulin secretory and/or pro-proliferative effects of Ccl4 in islet β-cells suggests that it is unlikely to play a role in regulating β-cell function via crosstalk between adipose tissue and islets. The divergent functional effects highlight that whilst MIN6 cells are a useful primary β-cell surrogate for some studies, primary islets should always be used to confirm physiological relevance. On the other hand, significant α-cell depletion following Ccl4 treatment suggests a cell-specific function within the islets. Furthermore, Ccl4 impaired adiponectin mRNA expression in adipocytes, although, how adipocyte function is affected as a result requires further investigation. Collectively, these data have contributed increased understanding of the role of obesity in modifying the expression of adipose tissue-derived islet GPCR peptide ligands
- …